Profile
Steven Caffé held several positions in the pharmaceutical industry, including Vice President of Global Regulatory Affairs & Medical Vigilance at Baxter International, Inc., Head of Global Regulatory Affairs & Patient Safety at MedImmune LLC, Vice President & Head of Global Regulatory Development at Aventis, Inc., Senior Vice President of Regulatory Affairs at Sucampo Pharmaceuticals LLC, and Chief Development & Regulatory Officer at AMAG Pharmaceuticals, Inc. Currently, he is serving as the Head of Regulatory Affairs at CRISPR Therapeutics AG.
Prior to his industry roles, Dr. Caffé obtained a doctorate degree from Université Pierre et Marie Curie.
Former positions of Steven Caffé
| Companies | Position | End |
|---|---|---|
| CRISPR THERAPEUTICS AG | General Counsel | 30/11/2023 |
| SUCAMPO PHARMACEUTICALS, INC. | General Counsel | 03/04/2018 |
| RA PHARMACEUTICALS, INC. | General Counsel | - |
| Sanofi Corp. | General Counsel | - |
| Aventis, Inc. | General Counsel | - |
Training of Steven Caffé
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| Private companies | 7 |
|---|---|
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
| Aventis, Inc. | |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
| Université Pierre et Marie Curie | Consumer Services |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
| Sanofi Corp. |
- Stock Market
- Insiders
- Steven Caffé
